Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors

Purpose of investigation: To determine the expression of matrix metalloproteinase-9 (MMP-9) expression in malignant and borderline ovarian tumors and its correlation to prognosis.

Methods: Forty-five patients with primary epithelial ovarian tumors were enrolled in this retrospective study from 1988 to 2002. Only malignant (n = 30) and borderline (n = 15) ovarian tumors constituted the study group. All cases were surgically staged according to FIGO criteria. Patient characteristics and clinico-pathological findings were obtained from hospital records. Paraffin-embedded tissue blocks were treated with MMP-9 immunohistochemical stain. The percentage of the total number of tumors staining positively was categorised and awarded a score of 0 to 4: < 5% as 0, < or = 6-25% as 1, 26-50% as 2, 51-75% as 3 and 76-100% as 4. The intensity of immunostaining was scored on a 3-point scale: 1, weak; 2, moderate and 3, intense. A weighed score for each tumor specimen was produced by multiplying the percentage score with the intensity score and was defined as the 'epithelial MMP-9 score'. Stromal staining was also assessed as weak, moderate and intense. Cases with final epithelial MMP-9 scores < or = 6 and > 6 were then recategorised into two groups, accordingly. Based on degree of stromal staining, cases were recategorised into two final groups as mildly stained and intense or moderately stained. Tumor stages were regrouped as early (Stage I-II) and late (Stage III-IV), respectively.

Results: Mean ages of cases with malignant and borderline ovarian tumors were 57.2 +/- 3.1 and 49.7 +/- 2.1 years, respectively. Epithelial MMP-9 scores were higher in malignant tumors compared to borderline tumors (p = 0.014). However, with regard to stromal MMP-9 staining, no significant difference was observed among malignant and borderline tumors (p = 0.113). Among malignant ovarian tumors, epithelial MMP-9 scores did not differ between early versus late-staged and well versus poorly differentiated tumors. Median survival time of cases with epithelial MMP-9 scores < or = 6 and > 6 were 24 months and 32 months, respectively (log-rank: 0.93, p = 0.335). Cases with weak stromal MMP-9 staining had a longer median survival (48 months) compared to cases with moderate or intense stromal MMP-9 staining (24 months, log-rank: 4.46, p = 0.03).

Conclusion: Epithelial MMP-9 expression generally appears in the malignant form of ovarian tumors compared to borderline tumors. MMP-9 expression in the stroma but not in the epithelium contributes to poor survival in ovarian cancers.

Matrix metalloproteinase-9; Epithelial ovarian cancer; Prognosis

[1] Niedbala M.J., Crickard K., Bernacki R.J.: "In vitro degradation of extracellular matrix by human ovarian carcinoma cells". Clin. Exp. Metast., 1987, 5, 181.

[2] Wu X., Li H., Kang L., Li L., Wang W., Shan B.: "Activated matrix metalloproteinase 2 - a potential marker of prognosis for epithelial ovarian cancer". Gynecol. Oneal., 2002, 84, 126.

[3] Tamakoshi K., Kikkawa F., Nawa A., Ishikawa H., Mizuno K., Tamakoshi A. et al.: "Characterisation of extracellular matrixdegrading proteinase and its inhibitor in gynecologic cancer tissues with clinically diffferent metastatic form". Cancer, 1995, 76 (12), 2565.

[4] Leber T.M., Balkwill F.R.: "Regulation of monocyte MMP-9 production by T NF-a and a tumor-derived soluble factor (MMPSF)". Br. J. Cancer, 1998, 78 (6), 724.

[5] Stacks M.S., Ellerbroek S.M., Fishman D.A.:'The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma (review)". Int. Oneal., 1999, 12, 569.

[6] Sinicrope F.A., Ruan S.B., Cleary K.R., Stephens L.C., Lee J.J., Levin B.: "Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis". Cancer Res., 1995, 55, 237.

[7] Huang L.W., Garrett P.A., Bell A.D., Welch R.W., Berkowitz S.R., Mok C.S.: "Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors". Gynecol. Oneal., 2000, 77, 369.

[8] Mignatti P., Rifkin D.B.: "Biology and biochemistry of protemases in tumor invasion". Physiol. Rev., 1993, 73, 161.

[9] Nagase H., Woesner J.F.: "Matrix metalloproteinases". J. Biol. Chem., 1999, 274, 21491.

[10] Bernhard E.J., Gruber S.B.. Muschel R.J.: "Direct evidence linking expression of matrix metalloproteinase 9 (92kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells". Proc. Nat. A cad. Sci. USA, 1994, 91, 4293.

[11] Brinckerho仆f E.C., Ruiter J.L., Benbow U.: "Interstitial collagenases as markers of tumor progression". Clin. Cancer Res., 2000, 6, 4823.

[12] Nelson A.R.. Fingleton B., Rothenberg M.L., Matrisian L.M.: "Matrix metalloproteinases: biologic activity and clinical implications". J. Clin. Oneal., 2000, 18 (5), 1135.

[13] Westerlund A., Sarrkkinen M.A., Horhtya M., Puistola U., Huganen T.T.: "Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer". Gynecol Oneal., 1999, 75, 91.

[14] Lengyel E., Schmalfeldt B., Konik E., Spathe K. et al.: "Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer". Gynecol. Oneal., 2001, 82, 291.

[15] Wu X., Li H., Li K., Li L.,Wang W., Sahn B.: "Activated matrix metalloproteinase-2- a potential marker of prognosis for epithelial ovarian cancer". Gynecol. Oncol., 2002, 84, 126.

[16] Davidson D., Goldberg I., Gotheb W.H. et al.: "High levels of MMP-2, MMP-9, MTI-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma". Clin. Exp. Metastasis, 1999, 17 (10), 799.

[17] Sakata K., Shigemasa K., Nagai N., Obama K.: "Expression of matrix metalloproteinase (MMP-2, MMP-9, MTI-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary". Int. J. Oneal., 2002, 17 (4), 673.

[18] Paju A., Soesa T., Tervahantiala T. et al.:'The levels of trypsmogen isoenzymes in ovarian tumor cysts are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation". Br. J. Cancer, 2001, 84 (10), 1363.

[19] Rodrigues G.C., Haisley C., Hurteau J. et al.: "Regulation of mvasion of epithelial ovarian cancer by tumor growth factor-beta". Gynecol. Oncol., 2001, 80 (2), 245.

[20] Ahmed N., Pansino F., Clyde R. et al.: "Overexpression of alpha(v) beta 6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade". Carcinogenesis, 2002, 23 (2), 237.

[21] Herrera C.A., Xu L., Bucana C.D., Silva el V.G., Gerhenson D.M., Fidler U.: "Expression of metastasis-related genes in human epithelial ovarian tumors". Int. J. Oneal., 2002, 20 (1), 5.

[22] Lynch C.C., Matrisian L.M.: "Matrix metalloproteinases in tumorhost cell communication". D,fferentiation, 2002, 70 (9-10), 561.

[23] Kurschat P., Mauch C.: "Mechanisms of metastasis". Clin. Exp. Dermatol., 2000, 25 (6), 482.

[24] Fingleton B., Vargo-Gogola T., Crawford H.C., Matrisian L.M.: "Matrilysin (MMP-7) expression selects for cells with reduced sensitivity to apoptosis". Neoplasia, 2001, 3 (6), 459.

[25] Coussens L.M., Fingleton B., Matrisian L.M.: "Matrix metalloproteinase inhibitors and cancer: trials and tribulations". Science, 2002, 295 (5564), 2387.